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Introduction
Although thromboembolism is uncommon during
pregnancy and the postpartum period, obstetricians
should be alert to the possibility because the com-
plications, such as pulmonary embolism (PE), are often
life-threatening. The estimated incidence of pregnancy-
associated venous thromboembolism (VTE) varies
from 1 in 1,000 to 1 in 2,000 deliveries [1]. PE occurs in
approximately 16% of patients with untreated deep
venous thrombosis (DVT) and remains the major cause
of maternal death in Western countries [2]. Hereditary
protein S deficiency is estimated to be associated with
about a tenfold increase in the risk of the first episode
of VTE in Caucasians [3]. Pregnancy is also a risk factor
for VTE in women with inherited thrombophilia. The
antepartum risk of VTE is thought to be 4% for carriers
of protein S deficiencies [4]. We present a case of
protein S deficiency diagnosed during pregnancy. The
patient experienced an episode of DVT of the left lower
extremity in her first pregnancy and an episode of PE in
her second pregnancy. We also discuss the prophylaxis
and treatment of VTE.
Case Report
A 28-year-old woman was referred to our hospital in her
first pregnancy at 9 weeks of gestation due to progressive
painful swelling of the left leg for 2 days. Vascular duplex
examination revealed DVT from the mid-femoral region
to above the knee in the left lower extremity. Her free
protein S level was 107% (normal, 44–115%) and her
functional protein S level was 36% (normal, 53–144%).
Other coagulation data such as antithrombin III (AT
III), protein C, lupus anticoagulant, and anticardiolipin
antibody were within normal limits. Protein S deficiency
was diagnosed. Low-molecular-weight heparin (LMWH)
was administered (fraxiparine 3,800 IU/0.4 mL twice
daily). She was discharged on the 16th day when the
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symptoms subsided, but received LMWH until delivery.
She had a normal spontaneous vaginal delivery at 38
weeks of gestation without complications. Postpartum
LMWH was continued for 2 months during the breast-
feeding period. Subsequently, despite taking warfarin
for 1.5 years, vascular duplex examination showed par-
tial thrombi in her left lower extremity.
The patient’s second pregnancy began 0.5 months
after warfarin was discontinued. At 6 weeks of gestation,
her free protein S level was 49% and her functional
protein S level was 45%. Prophylactic anticoagulant was
not given because of her stable condition. Unfortunately,
she was sent to our emergency department due to
dyspnea and aggravated left upper chest sharp pain at
11 weeks of gestation. At that time, D-dimer was 6.94
μg/mL (normal, < 0.5 μg/mL) and chest magnetic
resonance imaging revealed filling defects in bilateral
pulmonary arteries. Wedge-shaped high-intensity lesions
were noted in the superior segment of the left lower lobe
and left lingular segment. These findings were compatible
with PE. Her dyspnea and chest pain improved gradually
after LMWH therapy (clexane 60 mg/0.6 mL twice
daily). She tolerated room air well and her D-dimer level
dropped to 0.87 μg/mL within 6 days. She received
long-term LMWH until term normal spontaneous vaginal
delivery and during postpartum breast-feeding. The
delivery and postpartum courses were smooth.
Discussion
Protein S is a cofactor for the inactivation of factors Va
and VIIa by activated protein C [5]. It may also inhibit
a number of coagulation factors independently of protein
C. Protein S synthesis is vitamin K-dependent and occurs
in the liver. One-third of protein S circulates in a free
form and two-thirds is present as a complex with
complement 4b-binding protein [5]. Only the free form
is active.
Virchow postulated three main causes of thrombosis:
stasis of the blood, changes in the composition of the
blood, and changes in the vessel wall [6]. All three of
these conditions can occur in pregnancy and during
puerperium. Therefore, hypercoagulability and com-
pression of the venous system by the gravid uterus are
the major causes of VTE in pregnancy. Prophylactic
anticoagulant should be given in hemophiliac pregnant
women [7].
Anticoagulant regimens for pregnancy include
warfarin, unfractionated heparin (UFH) and LMWH.
Warfarin is a coumarin derivative that inhibits the action
of vitamin K. However, oral warfarin is contraindicated
in the first trimester because it crosses the placenta and
is teratogenic; its teratogenic effect is less during the
second and third trimesters. Warfarin can also cause
maternal and fetal bleeding and spontaneous fetal loss
[8]. Fetal intracranial hemorrhage is a possible severe
complication during the third trimester. Heparin can be
substituted from 6 to 12 weeks to eliminate embryo-
pathy, but activated partial thromboplastin time (aPTT)
should be monitored closely. Although limited data
indicate that warfarin cannot be detected in breast milk,
there is some uncertainty about its use in women who
are breast-feeding.
Heparin is the drug of choice for both prophylaxis
and treatment of VTE. However, the side effects of long-
term use of heparin in pregnant women include osteo-
porosis, thrombocytopenia, and an increased risk of
bleeding. UFH acts primarily by binding to AT III. The
resulting heparin-AT III complex inactivates several
coagulation enzymes [9]. Heparin dosage should be
adjusted to achieve an aPTT that is 1.5–2.5 times the
control value. If a therapeutic aPTT level cannot be
reached, an anti-Xa level (plasma heparin) of 0.3–0.7
U/mL 6 hours after the dose, equivalent to a heparin
level of 0.2–0.4 U/mL by protamine titration, should be
used [10].
LMWH acts primarily by exerting an anti-Xa effect. It
has a longer plasma half-life than UFH and provides a
more predictable dose response, which allows once- or
twice-daily administration. LMWH is also associated
with a lower risk of maternal osteopenia and throm-
bocytopenia than UFH [9]. These advantages over UFH
make LMWH the agent of choice for preventing and
treating VTE in pregnant women [11]. Since women
gain weight during pregnancy, the dosage of LMWH
should be adjusted. Bates and Ginsberg suggest three
dosing options [12]. First, the initial dose can be
maintained throughout pregnancy. Second, the dose
can be adjusted to account for weight gained over the
pregnancy. Third, heparin (anti-Xa) levels can be mea-
sured 4–6 hours after the morning dose on a periodic
basis.
In this case, protein S deficiency was diagnosed
during the episode of DVT at 9 weeks of gestation in the
patient’s first pregnancy. Her symptoms subsided after
LMWH treatment. An episode of PE occurred in her
second pregnancy at 11 weeks of gestation. Management
with LMWH was also successful. Women with hereditary
hypercoagulable states such as AT III or protein C and
S deficiencies and a previous episode of VTE are expected
to be at a higher risk of acute VTE during pregnancy
than asymptomatic carriers with these abnormalities.
Therefore, prophylactic anticoagulant therapy should
be given throughout the antepartum and postpartum
period. The newer LMWHs are the best choice because
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they can be administered once or twice daily, have a
predictable dose response, and do not require constant
monitoring. However, the cost of these agents may
somewhat limit their use. Long-term use of UFH or
LMWH can lead to osteoporosis, thrombocytopenia,
and an increased risk of bleeding. Oral warfarin can be
substituted in the second trimester and the postpartum
period. Warfarin should be used in patients with a
mechanical valve prosthesis.
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